调节器
肝细胞
富勒烯
衍生工具(金融)
化学
纳米技术
脂滴
生物物理学
细胞生物学
业务
材料科学
生物化学
生物
有机化学
基因
体外
财务
作者
Hongliang Li,Toujun Zou,Juan Wan,Rufang Liao,Weiyi Qu,Jinjie Yang,Xiang Zhang,Lan Bai,Junjie Zhou,Tian Tian,Qinchao Tang,Yufeng Zhang,Chong Zhao,Xinxin Yao,Zhiwei Cai,Song Tian,Jingwei Jiang,Xu Cheng,Yufeng Hu,Hailong Yang
出处
期刊:Research Square
日期:2023-09-18
标识
DOI:10.21203/rs.3.rs-3236361/v1
摘要
Abstract Lipid droplets (LDs) are crucial organelles in organisms and hold a critical function in modulating intracellular lipid metabolism and bioenergetic regulation. The homeostasis of LDs directly participates in the onset and progression of non-alcoholic steatohepatitis (NASH) and other metabolic disorders. However, no pharmacological approaches have been developed to target LDs-related dysfunction for metabolic diseases. Here, we systemically screened biocompatible nanoparticles for anti-LDs formation capacities, and identified a carboxyl fullerene derivative, named four malonate groups-substituted C70 fullerene (QF70), as the most potent lead. Notably, QF70 could be directly internalized into hepatocytes and facilitate lysosomal degradation of perilipin-2 (PLIN2), the key molecule in LDs formation and stability. More importantly, oral administration of QF70 robustly blocked both diet- and Leptin deficiency-induced NASH development with significant improvement in obesity and insulin resistance. We further validated the clinical application potential of QF70 in NASH related metabolic disorders in a non-primate model. To our knowledge, this is the first-in-class demonstration for a nanoparticle based agent as a LDs homeostasis-targeted therapeutic to treat metabolic diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI